 |
|
|
| |
International AIDS Conference
July 13-16, 2003, Paris |
| |
| |
- 2 Kaletra High-Dose Regimens in PI-Experienced: Pk and short-term viral response - (9/25/03)
- IAS: 96 week results of Trizivir vs Combivir/Nelfinavir vs d4T/3TC/Nelfinavir: Trizivir story is not over yet - Written by Judith Aberg, MD, Washington University, St. Louis, Missouri and the ACTG - (9/25/03)
- MaxCmin 2 study - Reported by Mike Youle, MD, Royal Free Hospital, London, UK - (8/11/03)
- SQV/r, ATV, ATV/r in Treatment-Experienced: boosted PI Therapy Antiretrovirals in subsequent regimens Written by Dr Graeme Moyle, London. Chelsea & Westminster Hospital - (8/4/03)
- MaxCmin2 Study: Kaletra vs saquinavir/ritonavir; final 48-week results - (8/4/03)
- HIV Viral Dynamics: viral fitness, genetic diversity, progresion, co-receptor use Written by Mike Youle, MD, Royal Free Hospital, London, UK - (8/4/03)
- New Atazanavir Information - (8/4/03)
- Pulmonary Hypertension: Finally a treatment trial! Reported by Judith Aberg, MD, Washington University, St Louis, Missouri, and the ACTG - (8/4/03)
- Viral Response to Peginterferon plus Ribavirin in Co-infection - (7/24/03)
- Antiretrovirals in First Line regimens: Trizivir, Sustiva, quad vs Triple therapy, Induction-Maintenance Reported by Dr Graeme Moyle, Chelsea & Westminster Hospital, London. - (7/24/03)
- Efavirenz (EFV) Well Tolerated: IAS Report Reported by Judith Aberg, MD , Washington University, St Louis, Missouri and the ACTG - (7/23/03)
- Recombinant Human Growth Hormone (r-hGH) Reported by Judith Aberg, MD , Washington University, St Louis, Missouri and the ACTG - (7/22/03)
- 10% Rate of HIV Drug Resistance in Newly Infected: genotype resistance testing suggested for newly infected - (7/21/03)
- Tenofovir: methadone & ribavirin interaction studies, and renal toxicity in 2 cases - (7/21/03)
- Trizivir-Efavirenz Induction-Maintenance Study - (7/21/03)
- Kaletra Update: Kaletra+Tenofovir+3TC Once Daily Study; Updated PHHS Guidelines on Preferred Regimens for First-Line Therapy - (7/21/03)
- Fuzeon Story: new 48 week study results; 24-week results hold up at week 48 - (7/17/03)
- Does Early HCV Kinetics Predict Response to Peginterferon and Ribavirin HCV Therapy among HIV Co-infected Individuals - (7/17/03)
- Reyataz+ritonavir vs Kaletra in treatment-experienced - (7/16/03)
- SPD754: new NRTI, early study results - (7/16/03)
- FTC: 60 week study results - (7/16/03)
- Fuzeon (T-20) Story - (7/15/03)
- ABC/AZT/3TC vs Efavirenz Based Regimens: ACTG 5095 - (7/14/03)
- High Viral failure Rates with Abacavir/3TC/Tenofovir Once Daily Regimen - (7/14/03)
|
|
| |
|
|
|
|
|
